Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): A comparison of two adapted BFM protocols
✍ Scribed by Sudhir Tauro; Lynda Cochrane; Grete Fossum Lauritzsen; Lee Baker; Jan Delabie; Claudia Roberts; Premini Mahendra; Harald Holte
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 92 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The chemotherapy dose‐intensity in two adapted German BFM paediatric protocols (BFM 90 and NHL 86) was compared in contemporaneously treated adults <50 years with Burkitt lymphoma and B‐cell lymphoma unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma (collectively referred to as BL). In BFM 90, primary prophylaxis with Granulocyte‐colony‐stimulating factor was used, postinduction treatment was started at granulocytes ≥0.5 × 10^9^/L (≥1.0 × 10^9^/L in NHL 86) with a higher mean methotrexate dose (2.9 g/m^2^/cycle, n = 23; 1.6 g/m^2^/cycle in NHL 86, n = 22, P < 0.001). Intervals between consecutive treatment‐cycles were shorter in BFM 90 (P < 0.001) with no additional toxicity. However, the two‐year failure‐free survival with BFM 90 (82%) was similar to that achieved with NHL 86 (72%, P = 0.33). We conclude that BFM 90 enables safe intensification of therapy in young adults with BL compared to NHL 86, but registry‐based studies are required to further evaluate the antineoplastic effects and cost‐effectiveness of the two therapeutic approaches. Am. J. Hematol., 2010. © 2010 Wiley‐Liss, Inc.